

Your request

You requested the following:

1. In the last 3 months (July, August, and September 2023), how many Haemophilia A, Haemophilia B and von Willebrand patients were treated in your trust with the following coagulation factors:
 - Hemlibra (non-inhibitor patients)
 - Hemlibra (inhibitor patients)
 - Advate
 - Adynovi
 - Elocta
 - Esperoct
 - NovoEight
 - ReFacto AF
 - Nuwiq
 - Idelvion
 - Refixia
 - Alprolix
 - BeneFIX
 - Replenine
 - Rixubis
 - Voncento
 - Veyvondi
 - Wilate
 - Willfact
 - Alphanate
 - Octanate
 - Optivate
 - Fahndi
 - Haemate
2. In the last 3 months (July, August, and September 2023), how much volume in IU or mg was used of the following coagulation factors:
 - Hemlibra (non-inhibitor patients)
 - Hemlibra (inhibitor patients)
 - Advate
 - Adynovi
 - Elocta
 - Esperoct

- NovoEight
- ReFacto AF
- Nuwiq
- Idelvion
- Refixia
- Alprolix
- BeneFIX
- Replenine
- Rixubis
- Voncento
- Veyvondi
- Wilate
- Willfact
- Alphanate
- Octanate
- Optivate
- Fahndi
- Haemate

3. In the last 3 months (July, August, and September 2023), how many patients switched from one of the following products to any other brand? Please indicate the brand that was switched to (i.e. Advate: 2 switches to Hemlibra, 3 switches to Elocta)

- Hemlibra (non-inhibitor patients)
- Hemlibra (inhibitor patients)
- Advate
- Adynovi
- Elocta
- Esperoct
- NovoEight
- ReFacto AF
- Nuwiq
- Idelvion
- Refixia
- Alprolix
- BeneFIX
- Replenine
- Rixubis
- Voncento
- Veyvondi
- Wilate
- Willfact
- Alphanate
- Octanate
- Optivate
- Fahndi
- Haemate

Our response

1. 2 patients were treated with Advate.
2. 8000 IU of Advate was used.
3. 0 patients switched between brands.